156 related articles for article (PubMed ID: 23526749)
21. Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma.
Jackson S; Patay Z; Howarth R; Pai Panandiker AS; Onar-Thomas A; Gajjar A; Broniscer A
J Neurooncol; 2013 Sep; 114(3):339-44. PubMed ID: 23813229
[TBL] [Abstract][Full Text] [Related]
22. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Gustafson DL; Frederick B; Merz AL; Raben D
Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
Secord AA; Teoh DK; Barry WT; Yu M; Broadwater G; Havrilesky LJ; Lee PS; Berchuck A; Lancaster J; Wenham RM
Clin Cancer Res; 2012 Oct; 18(19):5489-98. PubMed ID: 22837181
[TBL] [Abstract][Full Text] [Related]
24. Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children.
Anderson RC; Kennedy B; Yanes CL; Garvin J; Needle M; Canoll P; Feldstein NA; Bruce JN
J Neurosurg Pediatr; 2013 Mar; 11(3):289-95. PubMed ID: 23240851
[TBL] [Abstract][Full Text] [Related]
25. Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Cooper SL; Carter JJ; March J; Woolard J
Pharmacol Res Perspect; 2019 Jun; 7(3):e00477. PubMed ID: 31164986
[TBL] [Abstract][Full Text] [Related]
26. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
DeWire M; Fuller C; Hummel TR; Chow LML; Salloum R; de Blank P; Pater L; Lawson S; Zhu X; Dexheimer P; Carle AC; Kumar SS; Drissi R; Stevenson CB; Lane A; Breneman J; Witte D; Jones BV; Leach JL; Fouladi M
J Neurooncol; 2020 Sep; 149(3):511-522. PubMed ID: 33034839
[TBL] [Abstract][Full Text] [Related]
28. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
Sasaki T; Tanno S; Shibukawa K; Osanai S; Kawabe J; Ohsaki Y
Int J Oncol; 2008 Sep; 33(3):525-32. PubMed ID: 18695882
[TBL] [Abstract][Full Text] [Related]
29. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.
Aplenc R; Blaney SM; Strauss LC; Balis FM; Shusterman S; Ingle AM; Agrawal S; Sun J; Wright JJ; Adamson PC
J Clin Oncol; 2011 Mar; 29(7):839-44. PubMed ID: 21263099
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Martin P; Oliver S; Kennedy SJ; Partridge E; Hutchison M; Clarke D; Giles P
Clin Ther; 2012 Jan; 34(1):221-37. PubMed ID: 22206795
[TBL] [Abstract][Full Text] [Related]
31. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
[TBL] [Abstract][Full Text] [Related]
32. Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma.
Fried I; Lossos A; Ben Ami T; Dvir R; Toledano H; Ben Arush MW; Postovski S; Abu Kuidar A; Yalon M; Weintraub M; Benifla M
J Neurooncol; 2018 Jan; 136(1):189-195. PubMed ID: 29143272
[TBL] [Abstract][Full Text] [Related]
33. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.
Bergeron A; Réa D; Levy V; Picard C; Meignin V; Tamburini J; Bruzzoni-Giovanelli H; Calvo F; Tazi A; Rousselot P
Am J Respir Crit Care Med; 2007 Oct; 176(8):814-8. PubMed ID: 17600277
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
[TBL] [Abstract][Full Text] [Related]
35. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Kantarjian H; Cortes J; Kim DW; Dorlhiac-Llacer P; Pasquini R; DiPersio J; Müller MC; Radich JP; Khoury HJ; Khoroshko N; Bradley-Garelik MB; Zhu C; Tallman MS
Blood; 2009 Jun; 113(25):6322-9. PubMed ID: 19369231
[TBL] [Abstract][Full Text] [Related]
36. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas.
Bouffet E; Raquin M; Doz F; Gentet JC; Rodary C; Demeocq F; Chastagner P; Lutz P; Hartmann O; Kalifa C
Cancer; 2000 Feb; 88(3):685-92. PubMed ID: 10649264
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.
Pollack IF; Stewart CF; Kocak M; Poussaint TY; Broniscer A; Banerjee A; Douglas JG; Kun LE; Boyett JM; Geyer JR
Neuro Oncol; 2011 Mar; 13(3):290-7. PubMed ID: 21292687
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
[TBL] [Abstract][Full Text] [Related]
39. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
[TBL] [Abstract][Full Text] [Related]
40. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise?
Rizzo D; Scalzone M; Ruggiero A; Maurizi P; Attinà G; Mastrangelo S; Lazzareschi I; Ridola V; Colosimo C; Caldarelli M; Balducci M; Riccardi R
J Chemother; 2015 Feb; 27(2):106-10. PubMed ID: 25466729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
